Navigation Links
Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
Date:7/23/2009

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Company plans to host a conference call on Thursday, July 23, 2009 at 7:00 pm EDT (4:00 pm PDT). Members of Rigel's senior management team and the principal investigator of the trial will discuss results of the Company's Phase 2b TASKi3 clinical trial of R788 in rheumatoid arthritis, the Company's plans for further development and related matters.

Conference Call and Webcast Information

To access the live call, please dial 866-700-6293 (domestic) or 1-617-213-8835 (international) 10 minutes prior to the start time and use the passcode 13318888. A replay of the call will be available at approximately 10:00 pm EDT/7:00 pm PDT on July 23, 2009 until July 30, 2009. To access the replay, please dial 888-286-8010 (domestic) or 1-617-801-6888 (international) and use the passcode 14211103. The conference call will also be webcast live and can be accessed from Rigel's website athttp://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory/autoimmune diseases and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflamma
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Rigel to Present at Jefferies Healthcare Conference
2. Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers
3. Rigel to Present at JMP Securities Research Conference
4. Rigel to Present at Barclays Capital Healthcare Conference
5. Rigel Announces Fourth Quarter and Year End 2008 Financial Results
6. Rigel to Present at BIO CEO & Investor Conference
7. Rigel to Host Conference Call on February 3, 2009
8. Rigel to Present at Keystone Symposia Conference
9. Phase 2 Results of Rigels R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
10. Rigel to Present at the Piper Jaffray Annual Health Care Conference
11. Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... News) -- One in five American men admits ... a new survey shows. A nationally representative ... such violence is more prevalent than diabetes. This ... slapping and hitting, kicking, biting, choking, burning or ... said. Although abuse by high-profile professional athletes ...
(Date:9/16/2014)... School of Medicine researcher Dr. Jeffrey Samet and ... recently awarded a five year, $5 million grant ... their project titled: Improving Physician Opioid Prescribing for ... are the second most commonly abused substances in ... to prescription opioids now exceed deaths from motor ...
(Date:9/16/2014)... Since the adoption of pediatric legislation, ... in line with increased investment in R&D for pediatric ... novel paediatric information and more than 130 products have ... there has been 221 changes relating to the efficacy ... old or new trials in children and 89 additions ...
(Date:9/16/2014)... testing ground, researchers at Johns Hopkins have shown that ... can substantially reduce patient wait times and possibly improve ... report on the pilot study, published online Sept. 9, ... so-called "Just-in-Time" training and inventory process used now by ... keep complicated operations from bottlenecking. , "We realized that ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 RxAnte, ... predictive analytics and targeted clinical programs, today announced ... changes support the Company’s drive to improve medication ... targeted clinical programs. On September 2, 2014, Brock ... Millennium Health, announced that RxAnte founder and President ...
Breaking Medicine News(10 mins):Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3
... Rao, an American scientist of Indian origin has been ... a new system which makes use of data for ... is the Senior Director of Engineering Research Development at ... ,Rao is reported to have contributed towards ...
... drinkers go in for wholesome and healthy food, beer drinkers ... also seen among// wine drinkers when compared to beer ... in Copenhagen have found that beer drinkers buy unhealthy food ... prefer wine, according to BBC News. ,Studying ...
... Jefferson and colleagues from Cochrane Collaboration (International private organization ... trials) reviewed data from over 50 clinical trials involving ... researchers found that the old drugs which were used ... some drugs like amantadine and rimantidine which were used ...
... employ people with Asperger's Syndrome, who suffer from difficulties ... total of 50,000 people who suffer from this disorder, ... //People who suffer from the Asperger's Syndrome have difficulty ... though the intelligence of those who suffer from this ...
... Researchers from McMaster University has reported in the Journal ... found that the scientists screened 480 strains of Streptomyces ... all the strains were multi-drug resistance //as they were ... antibiotics. ,The researchers were astonished by ...
... transmission case is due today in Harbin court today. The ... blood collected from an infected couple who sold their blood ... Northeast China. // It was found that 15 people were ... and the other four got infection indirectly from the infected, ...
Cached Medicine News:
(Date:9/16/2014)... /PRNewswire-iReach/ -- Dan York has been named ... the RTD ® Advanced Wound Care Dressing, as ... presence in the U.S. Under York,s leadership, GWM Products, ... sales representatives in new sales territories that will complement ... up to 20 sales representatives in major metropolitan areas ...
(Date:9/16/2014)... Sept. 16, 2014 Adaptive Biotechnologies, a clinical ... to profile the adaptive immune system, is pleased to ... Chief Commercial Officer (CCO). The addition of Brain to ... hires from leading global healthcare companies, including Dean ... Counsel) from Genomic Health and Sean Nolan ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... present at the Sixth Annual JMP Securities Healthcare Conference on ... a.m. Pacific Time) at The St. Regis New York Hotel ... Executive Officer, is scheduled to provide a corporate overview. ...
... MINNEAPOLIS, Sept. 21, 2011 Uroplasty, Inc. (NASDAQ: ... markets innovative proprietary products to treat voiding dysfunctions, announced today ... President and CFO, will present the Company,s business strategy and ... at 2:30 PM ET on Tuesday, September 27, 2011 at ...
Cached Medicine Technology:Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 2Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 3Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: